NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT06008275 2025-11-10
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
NCT03012230 2024-01-31
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Mayo Clinic
Phase 1 Completed